Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9925976 | 1.00 | CYP2B6 (0.37) | CYP2B6NPC1HRH3ALDH1A1KMT2A | |
| SCHEMBL178517 | 0.97 | CYP2B6 (0.33) | CYP2B6NPC1HRH3TSHRTDP1 | |
| SCHEMBL18059326 | 0.92 | — | — | |
| SCHEMBL21121000 | 0.85 | HRH3 (0.38) | HRH3ALDH1A1TSHRTDP1 | |
| SCHEMBL24419835 | 0.82 | HRH3 (0.33) | HRH3 | |
| SCHEMBL21207913 | 0.80 | CYP2B6 (0.32) | CYP2B6NPC1 | |
| SCHEMBL22871678 | 0.80 | CYP2B6 (0.38) | CYP2B6NPC1KMT2A | |
| SCHEMBL23336586 | 0.80 | CYP2B6 (0.38) | CYP2B6NPC1KMT2A | |
| SCHEMBL11990045 | 0.79 | CYP2B6 (0.34) | CYP2B6NPC1 | |
| SCHEMBL18745418 | 0.79 | CYP2B6 (0.34) | CYP2B6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20210070703-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | UNIV DREXEL (US) | 2021-03-11 | — | — | US | disclosed |
| US-20190107534-A1 | AZETIDINE-SUBSTITUTED FLUORESCENT COMPOUNDS | HOWARD HUGHES MEDICAL INSTITUTE | 2019-04-11 | — | — | US | disclosed |
| US-9758477-B2 | Sulfamoylbenzamide derivatives as antiviral agents against HBV infection | DREXEL UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170137426-A1 | HETEROCYCLIC COMPOUNDS AS AXL INHIBITORS | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-4131469-A | POLYSTYRENE WITH QUATERNARY AMMONIUM SUBSTITUENTS | FUJI PHOTO FILM CO., LTD. (JP) | 1978-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | CYP2B6 889/4885NPC1 897/4885HRH3 2353/4885 |
| US-20170137426-A1 | HETEROCYCLIC COMPOUNDS AS AXL INHIBITORS | AXL, FLT3, MERTK | CYP2B6 3715/4885NPC1 4423/4885HRH3 3156/4885 |
| US-20210070703-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | ALKBH5, SULT1A1, SHMT1 | CYP2B6 94/4885NPC1 3197/4885HRH3 3945/4885 |
| US-20190107534-A1 | AZETIDINE-SUBSTITUTED FLUORESCENT COMPOUNDS | AANAT, HNMT, CHAT | CYP2B6 1190/4885NPC1 217/4885HRH3 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.